REQUEST A DEMO
Total
USD $0.00
Search more companies

Sanofi-Aventis Korea Co.,Ltd. (Seoul) (South Korea)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Sanofi-Aventis Korea Co.,Ltd. Profile Updated: December 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Sanofi-Aventis Korea Co.,Ltd. is engaged in supply and distribution of generic drugs, medical equipment and consumer healthcare products. The company offers prescription drugs and vaccines for diabetes, anticancer, thrombosis, cardiovascular diseases, central nervous system diseases, etc. Sanofi-Aventis Korea Co.,Ltd. is based in Seoul, South Korea. The company was established in 1991 and operates as a subsidiary of Sanofi S.A.

Headquarters
Banpo-daero Seocho-gu Seoul, 235
Seoul; Seoul;

Contact Details: Purchase the Sanofi-Aventis Korea Co.,Ltd. (Seoul) report to view the information.

Website: http://www.sanofi.co.kr

Basic Information
Total Employees:
Purchase the Sanofi-Aventis Korea Co.,Ltd. (Seoul) report to view the information.
Outstanding Shares:
Purchase the Sanofi-Aventis Korea Co.,Ltd. (Seoul) report to view the information.
Registered Capital:
Purchase the Sanofi-Aventis Korea Co.,Ltd. (Seoul) report to view the information.
Incorporation Date:
July 01, 1991
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
58.6%
Purchase this report to view the information.
19.6%
Purchase this report to view the information.
13.2%
Subsidiaries
Opella Healthcare Korea Inc.
100%
Company Performance
Financial values in the chart are available after Sanofi-Aventis Korea Co.,Ltd. (Seoul) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
3.66%
Total operating revenue
3.66%
Operating profit (EBIT)
96.52%
EBITDA
85.1%
Net Profit (Loss) for the Period
204.93%
Total assets
16.15%
Total equity
11.61%
Operating Profit Margin (ROS)
1.75%
Net Profit Margin
2.4%
Return on Equity (ROE)
6.59%
Debt to Equity Ratio
8.34%
Quick Ratio
-0.09%
Cash Ratio
-0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?